Quick Answer
BioNexus Gene Lab Corp reported Operating Income Loss of -$1.57 million for the year ending 2024.
- BioNexus Gene Lab Corp showed an increase of +39.3% in Operating Income Loss from 2023 to 2024.
- This data is from BioNexus Gene Lab Corp's annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$39.5 thousand | Q3 2018: -$55.1 thousand | Q1 2019: -$60.2 thousand | Q2 2019: -$69.2 thousand | Q3 2019: -$50.1 thousand | Q1 2020: $1.07 million | Q2 2020: -$34.0 thousand | Q3 2020: $237.3 thousand | Q1 2021: $342.1 thousand | Q2 2021: $140.0 thousand | Q3 2021: $372.6 thousand | Q1 2022: $34.7 thousand | Q2 2022: -$138.0 thousand | Q3 2022: -$65.2 thousand | Q1 2023: -$50.6 thousand | Q2 2023: -$272.2 thousand | Q3 2023: -$2.53 million | Q1 2024: -$79.0 thousand | Q2 2024: $259.2 thousand | Q3 2024: -$1.34 million | Q1 2025: -$618.4 thousand | Q2 2025: -$611.3 thousand | Q3 2025: -$702.5 thousand.
- Over the full 7 years of available data (2018 to 2024), BioNexus Gene Lab Corp's Operating Income Loss has declined by 2,727.2%.
- Historical annual values: Fiscal year 2024: -$1.57 million | Fiscal year 2023: -$2.59 million | Fiscal year 2022: -$291.2 thousand | Fiscal year 2021: $1.06 million | Fiscal year 2020: $1.27 million | Fiscal year 2019: -$275.7 thousand | Fiscal year 2018: $59.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: